BusinessAXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at HarvardBy Nasdaq OMXApr 13, 2017, 1:01 PM UTC
BusinessAXIM Biotech Advisory Board Member Presented at CannMed 2017 Personalized Cannabinoid Medicine Conference at HarvardBy Nasdaq OMXApr 13, 2017, 1:01 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces the Production of CanChew Plus™, the Next Generation Controlled Release CBD Chewing GumBy Nasdaq OMXMar 1, 2017, 2:01 PM UTC
BusinessAXIM Biotech Announces the Production of CanChew Plus™, the Next Generation Controlled Release CBD Chewing GumBy Nasdaq OMXMar 1, 2017, 2:01 PM UTC
BusinessAXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing GumBy Nasdaq OMXJan 18, 2017, 2:01 PM UTC
